Here's Why We Think TalkMed Group (SGX:5G3) Might Deserve Your Attention Today
Here's Why We Think TalkMed Group (SGX:5G3) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
對一些投機者來說,投資一家能夠扭轉命運的公司的興奮感是一個很大的吸引力,因此,即使是沒有收入、沒有利潤、有虧損記錄的公司,也可以設法找到投資者。但現實是,當一家公司每年虧損時,在足夠長的時間內,其投資者通常會從虧損中分擔自己的份額。虧損的公司尚未用利潤證明自己,最終外部資本的流入可能會枯竭。
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like TalkMed Group (SGX:5G3). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.
儘管處於科技股藍天投資時代,但許多投資者仍然採用更傳統的策略:購買TalkMed集團(新加坡證券交易所:5G3)等盈利公司的股票。儘管利潤不是投資時應考慮的唯一指標,但值得表彰能夠持續生產利潤的企業。
TalkMed Group's Earnings Per Share Are Growing
TalkMed 集團的每股收益正在增長
The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Over the last three years, TalkMed Group has grown EPS by 12% per year. That's a good rate of growth, if it can be sustained.
市場在短期內是一臺投票機,但從長遠來看是一臺權衡器,因此您預計股價最終將跟隨每股收益(EPS)的結果。因此,有很多投資者喜歡購買每股收益不斷增長的公司的股票。在過去的三年中,TalkMed集團的每股收益每年增長12%。如果可以持續的話,這是一個不錯的增長率。
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. On the revenue front, TalkMed Group has done well over the past year, growing revenue by 9.4% to S$84m but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders.
仔細檢查公司增長的一種方法是查看其收入以及利息和稅前收益(EBIT)利潤率如何變化。在收入方面,TalkMed集團在過去一年中表現良好,收入增長了9.4%,達到8400萬新元,但息稅前利潤率卻不那麼明顯,在過去的12個月中有所下降。因此,如果息稅前利潤率能夠穩定下來,那麼這種收入增長應該會爲股東帶來回報。
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
下圖顯示了該公司的收入和收入隨着時間的推移是如何發展的。點擊圖表查看確切的數字。
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240409/0-bcb7f7f7e217fedbf7e51aec1f1239ef-0-f7adfff72392ca3d318fddaabc7647d5.png/big)
While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check TalkMed Group's balance sheet strength, before getting too excited.
雖然看到利潤增長總是件好事,但你應該永遠記住,疲軟的資產負債表可能會捲土重來。因此,在過於興奮之前,先檢查一下TalkMed集團的資產負債表實力。
Are TalkMed Group Insiders Aligned With All Shareholders?
TalkMed 集團內部人士是否與所有股東保持一致?
Seeing insiders owning a large portion of the shares on issue is often a good sign. Their incentives will be aligned with the investors and there's less of a probability in a sudden sell-off that would impact the share price. So we're pleased to report that TalkMed Group insiders own a meaningful share of the business. Indeed, with a collective holding of 86%, company insiders are in control and have plenty of capital behind the venture. This should be seen as a good thing, as it means insiders have a personal interest in delivering the best outcomes for shareholders. That means they have plenty of their own capital riding on the performance of the business!
看到內部人士擁有已發行股票的很大一部分通常是一個好兆頭。他們的激勵措施將與投資者保持一致,突然拋售影響股價的可能性較小。因此,我們很高興地向大家報告,TalkMed Group內部人士擁有該業務的重要份額。事實上,公司內部人士的集體持股比例爲86%,掌握了控制權,並有充足的資金支持該合資企業。這應該被視爲一件好事,因爲這意味着爲股東創造最佳業績符合內部人士的個人利益。這意味着他們有充足的自有資金來支撐企業的業績!
Should You Add TalkMed Group To Your Watchlist?
您是否應該將 TalkMed 群組添加到您的關注列表?
As previously touched on, TalkMed Group is a growing business, which is encouraging. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. We should say that we've discovered 2 warning signs for TalkMed Group (1 is concerning!) that you should be aware of before investing here.
如前所述,TalkMed集團是一家成長中的企業,這令人鼓舞。另一亮點是該公司擁有大量的內部所有權,這爲火上澆油。這兩個因素對公司來說是一個巨大的亮點,它應該是你的關注清單的有力競爭者。我們應該說我們已經發現了 TalkMed Group 的 2 個警告信號(1 個令人擔憂!)在這裏投資之前,您應該注意這一點。
Although TalkMed Group certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with insider buying, then check out this handpicked selection of Singaporean companies that not only boast of strong growth but have also seen recent insider buying..
儘管TalkMed Group看起來確實不錯,但如果內部人士買入股票,它可能會吸引更多的投資者。如果你想看看有內幕買入的公司,那麼看看這些精心挑選的新加坡公司,這些公司不僅擁有強勁的增長,而且最近也出現了內幕買盤。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。